Treace Medical (TMCI) Concepts commented on the recently released Centers for Medicare & Medicaid Services Calendar Year 2025 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Final Rule, effective January 1, 2025. The Final Rule and accompanying Addenda include the reassignment of Current Procedural Terminology code 28297 to Ambulatory Payment Classification code 5115 with a hospital outpatient payment rate of $12,867 for 2025. This represents an increase of $6,050, or 89%, over 2024. In the ASC setting, the 2025 payment is $9,820, an increase of 100%, compared to $4,900 for 2024. “As the pioneer of the market leading Lapiplasty 3D Bunion Correction System, we are pleased that the final rule recognizes the value that Lapidus fusion offers patients suffering from painful, lifestyle-limiting bunion deformities,” said John T. Treace, CEO.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical announces limited release of Nanoplasty 3D MIS Bunion Correction
- TMCI Upcoming Earnings Report: What to Expect?
- Treace Medical participates in a conference call with BTIG
- Treace Medical Sues Stryker Over Patent Infringement
- Boeing to cut 10% of workforce, Lundbeck to acquire Longboard: Morning Buzz